Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.6 (
CAD
)
4,420
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Purpose:
Aim of this study was to comprehensively analyze BRCA1-associated protein-1 (
BAP1
) somatic mutation in clear cell renal cell carcinoma (ccRCC) and explore potential therapeutic pathways and molecules.
Patients and methods:
In this study, we analyzed 445 ccRCC cases from The Cancer Genome Atlas (TCGA). Comprehensive analysis including survival, transcriptome and methylation between
BAP1
mutated and wild-type cases was performed using bioinformatics tools
in silico
. Pathways and molecules related to
BAP1
mutation were analyzed using Database for Annotation, Visualization and Integrated Discovery (DAVID) and protein-protein interaction (PPI) network.
Results:
BAP1
mutated ccRCC patients had a worse overall survival (OS) and disease free survival (DFS) than
BAP1
wild-type patients. We found 583 up-regulated and 1216 down-regulated different expressed genes (DEGs) in
BAP1
mutated tumors. Up-regulated DEGs were enriched in molecular functions and biological processes like protein binding, protein transport and ubiquitin protein ligase binding. Down-regulated DEGs were enriched in pathways like Rap1 signaling pathway, Notch pathway and altered molecular functions like metal ion binding and ubiquitin-protein transferase activity. Furthermore,
CAD
,
TSPO
, CTNNB1
and
MAPK3
were top hub genes selected using PPI network analysis. Finally,
BAP1
mutation had a strong correlation with CpG island methylator phenotype (CIMP).
Conclusion:
Our study provides a comprehensive understanding of
BAP1
functional somatic mutation in ccRCC patients. Several hub genes like
CAD
and
TSPO
may become potential therapeutic targets.
...
PMID:Comprehensive Analysis of
BAP1
Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms
in Silico
. 3051 10